MX2020007748A - Metodos para tratar canceres con anticuerpos anti-pd-1 antagonistas. - Google Patents

Metodos para tratar canceres con anticuerpos anti-pd-1 antagonistas.

Info

Publication number
MX2020007748A
MX2020007748A MX2020007748A MX2020007748A MX2020007748A MX 2020007748 A MX2020007748 A MX 2020007748A MX 2020007748 A MX2020007748 A MX 2020007748A MX 2020007748 A MX2020007748 A MX 2020007748A MX 2020007748 A MX2020007748 A MX 2020007748A
Authority
MX
Mexico
Prior art keywords
antibodies
methods
treating cancers
antagonistic anti
antagonistic
Prior art date
Application number
MX2020007748A
Other languages
English (en)
Inventor
Edward F Attiyeh
Kyounghwa Bae
James G Greger
Hong Xie
Christina Lourdes Mayer
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2020007748A publication Critical patent/MX2020007748A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invencion se relaciona con metodos para tratar canceres con anticuerpos anti-PD-1 antagonistas, formulaciones de los anticuerpos anti-PD-1 antagonistas y productos farmacológicos de los anticuerpos anti-PD-1.
MX2020007748A 2018-01-22 2019-01-19 Metodos para tratar canceres con anticuerpos anti-pd-1 antagonistas. MX2020007748A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862620106P 2018-01-22 2018-01-22
US201962794195P 2019-01-18 2019-01-18
PCT/IB2019/050449 WO2019142149A2 (en) 2018-01-22 2019-01-19 Methods of treating cancers with antagonistic anti-pd-1 antibodies

Publications (1)

Publication Number Publication Date
MX2020007748A true MX2020007748A (es) 2020-09-25

Family

ID=65529735

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007748A MX2020007748A (es) 2018-01-22 2019-01-19 Metodos para tratar canceres con anticuerpos anti-pd-1 antagonistas.

Country Status (16)

Country Link
US (1) US20190225689A1 (es)
EP (1) EP3743159A2 (es)
JP (1) JP2021511341A (es)
KR (1) KR20200112867A (es)
CN (1) CN111629788A (es)
AU (1) AU2019208537A1 (es)
BR (1) BR112020014618A2 (es)
CA (1) CA3089174A1 (es)
IL (1) IL275897A (es)
JO (1) JOP20200177A1 (es)
MA (1) MA51677A (es)
MX (1) MX2020007748A (es)
PH (1) PH12020500576A1 (es)
SG (1) SG11202006422PA (es)
WO (1) WO2019142149A2 (es)
ZA (1) ZA202005223B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230355757A1 (en) 2019-12-20 2023-11-09 Formycon Ag Formulations of anti-pd1 antibodies
TW202140012A (zh) 2020-02-12 2021-11-01 比利時商健生藥品公司 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑
GB2609879B (en) 2020-05-07 2023-08-16 Adorx Therapeutics Ltd Antagonists of the adenosine A2a receptor
GB202011996D0 (en) 2020-07-31 2020-09-16 Adorx Therapeutics Ltd Antagonist compounds
CN112194723B (zh) * 2020-09-25 2021-09-21 广州百吉生物制药有限公司 一种免疫细胞在治疗癌症中应用
GB202019622D0 (en) 2020-12-11 2021-01-27 Adorx Therapeutics Ltd Antagonist compounds
CN115466328A (zh) * 2021-06-11 2022-12-13 广东菲鹏制药股份有限公司 抗pd-1人源化抗体或其抗原结合片段及其应用
EP4359001A1 (en) 2021-06-23 2024-05-01 Formycon AG Formulations of anti-pd1 antibodies
GB2615307A (en) 2022-01-28 2023-08-09 Adorx Therapeutics Ltd Antagonist compounds
WO2024133625A1 (en) 2022-12-21 2024-06-27 Formycon Ag Formulations of anti-pd1 antibodies
WO2024171082A1 (en) 2023-02-16 2024-08-22 Sun Pharmaceutical Industries Limited Stable protein compositions of anti-pd1 antibody

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1916303B1 (en) 2000-11-30 2013-02-27 Medarex, Inc. Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice
CA2491864C (en) 2001-07-12 2012-09-11 Jefferson Foote Super humanized antibodies
BRPI0707796A2 (pt) * 2006-02-15 2011-05-10 Imclone Systems Inc formulaÇço, e, mÉtodo de tratamento
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
CN101970730A (zh) 2007-12-19 2011-02-09 森托科尔奥索生物科技公司 通过融合到pⅨ或pⅦ来设计和生成人从头pⅨ噬菌体展示文库,载体、抗体及方法
US20100261620A1 (en) 2008-10-14 2010-10-14 Juan Carlos Almagro Methods of Humanizing and Affinity-Maturing Antibodies
AU2013212587B2 (en) * 2012-01-23 2017-07-20 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-Ang2 antibodies
WO2014031718A1 (en) * 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
US10392438B2 (en) * 2014-05-16 2019-08-27 Pfizer Inc. Bispecific antibodies
US20180155429A1 (en) * 2015-05-28 2018-06-07 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
EP3353202B1 (en) * 2015-09-24 2020-11-04 Teva Pharmaceuticals International GmbH Preventing, treating, and reducing (persistent) post-traumatic headache
WO2017055966A1 (en) * 2015-10-01 2017-04-06 Pfizer Inc. Low viscosity antibody compositions
CR20180234A (es) * 2015-11-03 2018-09-11 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
CA3009001A1 (en) * 2016-01-11 2017-07-20 Universitat Zurich Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
ES2897964T3 (es) * 2016-06-03 2022-03-03 Bristol Myers Squibb Co Uso del anticuerpo anti-PD-1 en el tratamiento de pacientes con cáncer colorrectal
EP3624896A4 (en) 2017-05-16 2021-03-31 Biomed Valley Discoveries, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER WITH ATYPICAL BRAF MUTATIONS

Also Published As

Publication number Publication date
IL275897A (en) 2020-08-31
BR112020014618A2 (pt) 2020-12-08
KR20200112867A (ko) 2020-10-05
CA3089174A1 (en) 2019-07-25
WO2019142149A2 (en) 2019-07-25
AU2019208537A1 (en) 2020-07-09
JP2021511341A (ja) 2021-05-06
MA51677A (fr) 2020-12-02
ZA202005223B (en) 2022-03-30
JOP20200177A1 (ar) 2020-07-19
EP3743159A2 (en) 2020-12-02
US20190225689A1 (en) 2019-07-25
PH12020500576A1 (en) 2021-05-17
WO2019142149A3 (en) 2019-09-26
SG11202006422PA (en) 2020-08-28
CN111629788A (zh) 2020-09-04

Similar Documents

Publication Publication Date Title
MX2020007748A (es) Metodos para tratar canceres con anticuerpos anti-pd-1 antagonistas.
AU2018263868A1 (en) Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2018016364A (es) Anticuerpos anti-pd-l1.
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
MX2022013524A (es) Anticuerpos neutralizantes para el virus de inmunodeficiencia humana.
MX2023002588A (es) Anticuerpos anti-tgf-beta y su uso.
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
MY191581A (en) Anti-pd-1 antibodies
NZ738008A (en) Tigit-binding agents and uses thereof
MX2018003936A (es) Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones.
MX2021010471A (es) Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr.
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
PH12020551716A1 (en) Anti-ror antibody constructs
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
MX2020008122A (es) Anticuerpos anti-pd-1.
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
MX2020002802A (es) Anticuerpos de cadena pesada que se unen a ectoenzimas.
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.